Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
Background: There is inconsistency in the criteria used to define anti-vascular endothelial growth factor (VEGF) drug-induced hypertension (AVEGF-HT) in published studies. It is unknown whether specific patient characteristics similarly predict AVEGF-HT using different criteria. Methods: We assessed...
Main Authors: | Arduino A. Mangoni, Ganessan Kichenadasse, Andrew Rowland, Michael J. Sorich |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-02-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834018755090 |
Similar Items
-
Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
by: Ashley M. Hopkins, et al.
Published: (2020-02-01) -
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
by: Ashley M Hopkins, et al.
Published: (2020-06-01) -
Atenolol as an anti-hypertensive drug.
by: Kale P, et al.
Published: (1985-10-01) -
Placental malaria: hypertension, VEGF, and prolactin.
by: Roy Douglas Pearson
Published: (2007-03-01) -
Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
by: Andrew E. C. Booth, et al.
Published: (2020-07-01)